Skip to content
PubMed This is a summary of 147 peer-reviewed journal articles Updated
Oncology

Lung Cancer: A Patient Guide

At a Glance

Lung cancer care is personalized: doctors use the cancer’s type, stage, biomarker results, overall health, and treatment goals to guide choices among surgery, radiation, medicines, clinical trials, and supportive care.

Lung cancer is a complex disease that begins when cells in the lungs change and grow out of control, eventually forming a mass called a tumor. While it was once treated as a single condition, doctors now understand that lung cancer is a diverse collection of diseases defined by their specific cellular makeup and genetic drivers [1]. The two primary categories are Non-Small Cell Lung Cancer (NSCLC), which is the most common form, and Small Cell Lung Cancer (SCLC), which tends to grow and spread more rapidly [2]. Understanding which type you have is the first step in creating an effective roadmap for your care.

Modern lung cancer care has moved away from a “one-size-fits-all” model toward highly personalized medicine. The most critical part of this process is comprehensive biomarker testing, which looks at the unique genetic “fingerprints” of your specific tumor [3]. By identifying these markers, your medical team can often select targeted therapies or immunotherapies that may target cancer more selectively than traditional chemotherapy, but all treatments can cause important side effects [4]. When it is medically safe, clinicians often try to obtain the relevant biomarker results before choosing systemic therapy, as it helps ensure the first therapy is the most appropriate [5]. However, if you have rapidly progressive symptoms or Small Cell Lung Cancer, your doctors may need to start treatment urgently before all tests return.

Treatment depends on cancer type, stage, biomarkers, overall health, and patient preferences; this guide is intended to inform you but is not a substitute for individualized medical advice. Because lung cancer treatment often involves multiple approaches—such as surgery, radiation, and systemic medications—you will be supported by a multidisciplinary team of specialists [6]. This team works together to manage the disease while also focusing on your quality of life, incorporating palliative and supportive care from the very beginning. Today, the outlook for patients is more hopeful than ever before; advancements in research have led to a massive expansion of treatment options, allowing many people to live longer, more active lives following their diagnosis [7]. You are entering a landscape of care that is rapidly evolving, with new breakthroughs and supportive resources available to help you navigate every stage of the journey [8].

Common questions in this guide

What are the main types of lung cancer, and why does the type matter?
The two main categories are non-small cell lung cancer, which is the most common, and small cell lung cancer, which tends to grow and spread more quickly. Identifying the type helps the care team choose appropriate tests and treatment strategies.
Why is biomarker testing important for lung cancer?
Biomarker testing looks for genetic features in a tumor that may help doctors select targeted therapy or immunotherapy. When it is medically safe, teams often try to obtain these results before starting systemic treatment so the first therapy is better matched to the cancer.
What happens if my lung cancer biomarker results are delayed?
Your doctors weigh the urgency of treatment against the value of waiting for test results. If symptoms are progressing rapidly or the cancer is small cell lung cancer, treatment may need to begin before all biomarker results are available.
What factors determine my lung cancer treatment plan?
Treatment depends on the cancer’s type and stage, biomarker results, overall health, and personal preferences. Care may combine surgery, radiation, and systemic medicines, with recommendations developed by a multidisciplinary team.
Can palliative and supportive care start at the beginning of lung cancer treatment?
Yes. Palliative and supportive care can be incorporated from the beginning alongside cancer treatment to support quality of life and help address the effects of the illness or its treatment.
Should I ask about clinical trials or a second opinion for lung cancer?
It is reasonable to ask whether clinical trials at your treatment center may fit your diagnosis and goals. You can also discuss whether a second opinion would help you feel comfortable with your care plan and options.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific subtype of lung cancer do I have, and how does that influence our initial approach?
  2. 2.Has my tumor been sent for comprehensive biomarker testing (NGS), and what should we do if results are delayed?
  3. 3.Who will be my main point of contact, such as a nurse navigator, to help coordinate my treatments?
  4. 4.Are there clinical trials available at this center that might be a good fit for my diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (8)
  1. 1

    The impact of cancer information overload on negative emotions in newly diagnosed lung cancer patients: the mediating role of fear of progression and the moderating role of social support.

    Xu F, Zhang J, Li Q, et al.

    Frontiers in psychiatry 2025; (16()):1676219 doi:10.3389/fpsyt.2025.1676219.

    PMID: 41234423
  2. 2

    Lung cancer biomarkers.

    Mangang KN, Rao GSNK

    Clinica chimica acta; international journal of clinical chemistry 2026; (580()):120707 doi:10.1016/j.cca.2025.120707.

    PMID: 41213493
  3. 3

    Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

    Lindeman NI, Cagle PT, Aisner DL, et al.

    The Journal of molecular diagnostics : JMD 2018; (20(2)):129-159 doi:10.1016/j.jmoldx.2017.11.004.

    PMID: 29398453
  4. 4

    Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine.

    Villaruz LC, Socinski MA, Weiss J

    Frontiers in oncology 2023; (13()):1124167 doi:10.3389/fonc.2023.1124167.

    PMID: 37077826
  5. 5

    TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer.

    Okamoto I, Kuyama S, Girard N, et al.

    Future oncology (London, England) 2024; (20(37)):2927-2936 doi:10.1080/14796694.2024.2409621.

    PMID: 39469838
  6. 6

    Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.

    Salgia R

    Future oncology (London, England) 2015; (11(3)):489-500 doi:10.2217/fon.14.275.

    PMID: 25675128
  7. 7

    Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer.

    Spicer JD, Cascone T, Wynes MW, et al.

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024; (19(10)):1373-1414 doi:10.1016/j.jtho.2024.06.010.

    PMID: 38901648
  8. 8

    Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

    Ettinger DS, Wood DE, Aisner DL, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(5)):497-530.

    PMID: 35545176

This guide is for informational purposes only and does not constitute medical advice. Your lung cancer care team can interpret your diagnosis and recommend treatment based on your type, stage, biomarkers, health, and goals.

Get notified when new evidence is published on lung cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.